Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study

Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation

PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 6, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on February 7, 2023. The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series C Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series C Preferred Stock).

Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock

Fourth Quarter 2022 Twirla Factory Sales Expected to Increase Approximately 30% from Third Quarter 2022

Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Chairman and Chief Executive Officer Al Altomari will present a corporate overview at the conference on Monday, December 5 at 3:20 p.m. ET.

Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference

Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Amy Welsh - Chief Commercial Officer Jason Butch - Chief Accounting Officer Conference Call Participants Oren Livnat - H.C. Wainwright Nazibur Rahman - Maxim Group LLC Operator Good afternoon, and welcome to the Agile Therapeutics Third Quarter 2022 Financial Results Conference Call.

Agile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call Transcript

Net Revenue Increased 43% from Second Quarter 2022

Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022

Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth

Agile Therapeutics Announces Reorganization of Leadership Team

PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York, NY. Details on the Company presentation are as follows:

Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Baudax Bio

Clarus Therapeutics Holdings

Nine Energy Service

Quanergy Systems

Revelation Biosciences

Alaunos Therapeutics

Trevi Therapeutics Inc

Mammoth Energy Services

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing Conference Call Participants Oren Livnat - H.C. Wainright Operator Good afternoon, and welcome to the Agile Therapeutics Second Quarter 2022 Financial Results Conference Call.

Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q2 2022 Results - Earnings Call Transcript

Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022

Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range

Agile Therapeutics Updates Second Quarter 2022 Guidance

Iterum Therapeutics Plc

RedHill Biopharma

T2 Biosystems

More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch

PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest. Full details on the panel are as follows:

Agile Therapeutics to Participate in Maxim Group's Upcoming Women's Health Panel

AcelRx Pharmaceuticals

Allena Pharmaceuticals

Here's what you need to know about trading penny stocks on July 6th The post What to Know About Buying Penny Stocks on July 7th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 7th

PRINCETON, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previously announced upsized public offering of an aggregate of 26,666,666 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock warrants, at a public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrants. Each share of common stock (or pre-funded warrant) was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.90 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.90 per share. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $24.0 million.

Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock warrants, at a public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrants. Each share of common stock (or pre-funded warrant) was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.90 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.90 per share. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $24.0 million.

Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering

Evofem Biosciences Inc

Femasys

Here's what you need to know about buying penny stocks on June 28th The post What to Know About Buying Penny Stocks on June 28th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 28th

Acutus Medical

Cybin

Hillstream Biopharma

Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL. Details on the Company presentation are as follows:

Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference

Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q1 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman, CEO Dennis Reilly - CFO Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good afternoon, and welcome to the Agile Therapeutics' First Quarter 2022 Financial Results Conference Call.

Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q1 2022 Results - Earnings Call Transcript

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system (LNG/EE TDS).

Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022

A 1-for-40 reverse stock split of Agile Therapeutics, Inc. (Nasdaq: AGRX) has gone into effect. These are the details.

Agile Therapeutics (AGRX) Stock: 1-For-40 Reverse Stock Split Goes Into Effect

News for Agile Therapeutics Stock (AGRX)